STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £55.86m
- £68.28m
- $49.70m
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update
Shield Therapeutics - ACCRUFeR® Phase 3 pediatric trial published
Shield Therapeutics - Grant of Share Options
Brief: Shield Therapeutics Reports Q1 2026 Group Net Revenues Of $18 Million
Shield Therapeutics - Q1 2026 Trading Update
Brief: Shield Therapeutics Reports 2025 Group Net Revenues & Other Income At $49.7 Million
Shield Therapeutics - Audited results for year ended 31 December 2025
RCS - Shield Therapeutics - Publication of Report, Reinforcing FDA Approval
Brief: Shield Therapeutics Says Fda Approves Accrufer Oral Iron For Children 10 And Older
Brief: Shield Therapeutics Says FDA Grants Additional Exclusivity For ACCRUFeR
Brief: Shield Therapeutics Announces Approval For ACCRUFeR In China Expected In Q1 2026
Brief: Shield Therapeutics Expects to Deliver Operating Profit In 2026
Shield Therapeutics - Q4 2025 Trading Update
Brief: Shield Therapeutics Announces FDA Approval Of Extension For ACCRUFeR
Shield Therapeutics - FDA approves extension for ACCRUFeR®
Shield Therapeutics - Block Listing Application